Neratinib is a tyrosine kinase inhibitor targeting HER1, HER2, and HER4 and can effectively improve disease-free survival of HER2-positive breast cancer patients given with chemotherapy and trastuzumab [55, 56]. This evidence concerns the gene ERBB4 and breast carcinoma.